Trade Report: Today, Raymond James Financial Inc. Downgraded Nivalis Therapeutics Inc. (NVLS) to Market Perform

Today, Raymond James Financial Inc. Downgraded Nivalis Therapeutics Inc. (NVLS) to Market Perform

Nivalis Therapeutics Inc. (NASDAQ:NVLS) was downgraded by investment analysts at Raymond James Financial Inc. from an “outperform” rating to a “market perform” rating in a report released on Tuesday.

A number of other research firms have also recently commented on NVLS. HC Wainwright reaffirmed a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 8th. Zacks Investment Research cut shares of Nivalis Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 12th. Stifel Nicolaus cut shares of Nivalis Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $16.00 to $3.25 in a research note on Tuesday. Cowen and Company cut shares of Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, Robert W. Baird cut shares of Nivalis Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $29.00 to $3.00 in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $9.60.

Nivalis Therapeutics (NASDAQ:NVLS) traded down 54.112% during midday trading on Tuesday, hitting $2.868. 1,883,302 shares of the stock were exchanged. Nivalis Therapeutics has a 12 month low of $2.78 and a 12 month high of $9.46. The firm’s 50 day moving average price is $6.46 and its 200 day moving average price is $5.84. The company’s market cap is $44.58 million.

Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.11. On average, equities research analysts forecast that Nivalis Therapeutics will post ($2.10) earnings per share for the current fiscal year.

In related news, EVP David Malcom Rodman sold 5,820 shares of Nivalis Therapeutics stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total transaction of $46,327.20. Following the completion of the sale, the executive vice president now owns 18,056 shares in the company, valued at approximately $143,725.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.00% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. BVF Inc. IL raised its stake in shares of Nivalis Therapeutics by 24.5% in the second quarter. BVF Inc. IL now owns 1,926,443 shares of the company’s stock worth $8,862,000 after buying an additional 379,700 shares during the last quarter. Opaleye Management Inc. raised its stake in shares of Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock worth $1,287,000 after buying an additional 160,000 shares during the last quarter. AXA raised its stake in shares of Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock worth $2,455,000 after buying an additional 139,652 shares during the last quarter. Endurant Capital Management LP raised its stake in shares of Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in shares of Nivalis Therapeutics during the third quarter worth $1,664,000. Institutional investors own 79.26% of the company’s stock.

About Nivalis Therapeutics

Related posts

Leave a Comment